Navigation Links
Cogent trial shows lack of adverse interaction between clopidogrel and stomach medicine
Date:9/24/2009

SAN FRANCISCO, CA SEPTEMER 24, 2009 Results from a late breaking clinical trial called COGENT demonstrate that the combination of giving patients clopidogrel, a blood thinner commonly prescribed to patients with cardiovascular disease, and stomach medicines such as omeprazole, known as proton pump inhibitors (PPIs), did not lead to adverse events, as some prior studies had suggested. The results were presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

COGENT is the first randomized assessment of administering clopidogrel and PPIs, which reduce the production of gastric acid, on clinical events. The trial involved 3,627 patients at 393 sites. Follow up was limited due to early termination of the trial.

Internal bleeding is a common adverse effect of antiplatelet or blood thinner therapies, such as clopidogrel. The gastrointestinal tract is the most common location for this type of bleeding, which often occurs in the form of peptic ulcer disease. The purpose of the trial was to determine whether the administration of clopidogrel and omeprazole is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer disease in the setting of concomitant aspirin therapy.

The primary endpoint of the trial was a composite of upper gastrointestinal clinical events, including gastroduodenal bleeding, symptomatic gastroduodenal ulcer, and persistent pain with multiple gastric erosions, obstruction or perforation.

There was a significant reduction in gastrointestinal events with PPI use. This had not been previously demonstrated in patients receiving aspirin and clopidogrel.

"Further research is needed to define the optimal strategy to reduce GI events in patients on antithrombotic therapy, though prophylactic PPI use seems promising," said lead investigator, Deepak L. Bhatt, MD, MPH, Chief of Cardiology at VA Boston Healthcare System and Director, Integrated Interventional Cardiovascular Program at Brigham and Women's Hospital and the VA Boston Healthcare System.


'/>"/>

Contact: Judy Romero
jromero@crf.org
347-407-2774
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
2. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
3. Varian Medical Systems Teams With Cogent Health Solutions to Offer Case Management Software for Cancer Survivorship
4. New Heart Pump Shows Promise in Trial
5. Trial to Test Gene Therapy for Angina in Women
6. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
7. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. MDS Pharma Services Wins Award for Management of Global Malaria Trial
10. New Ovarian Cancer Drug Trial Under Way
11. Study Questions Dead-End Cancer Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Gym Source, America’s leading retailer of premium ... South Dixie Hwy in Miami, FL. , “We are elated to be opening this ... in-store concept is designed to give clients a seamless and motivating shopping experience.” , ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... improved supplement, Healthful-Flex. , The company, owned and operated by Ed Stroup, ... at a reasonable price with the highest level of customer service. Healthful Balance ...
(Date:1/17/2017)... ... ... Kevin Harrington (one of the original Sharks from mega-hit reality series Shark ... of Beauty and Personal Care. , Everyone makes New Year’s resolutions ... to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will be ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... 21st century approach to infusing high speed technology into the fabric of an ... to the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Future published a Half Cooked Research Report on Endoscopy Devices Market. ... million during the period 2016 to 2022 from USD 28.7 million ... ... as a swiftly growing market and expected to grow at a ... various regions.  The increasing growth in endoscopy procedures is influencing the ...
(Date:1/17/2017)... 17, 2016  Attorney Advertising -- Bronstein, Gewirtz & Grossman, ... Anthera Pharmaceuticals, Inc. ("Anthera" or the "Company") (NASDAQ: ... and assist the investigation by visiting the firm,s site: ... certain of its officers and/or directors have violated Sections 10(b) ... ...
(Date:1/17/2017)... 17, 2017  In a letter to President-elect ... Jenkins outlines AARP,s priorities for Americans age 50 ... access to affordable health care coverage, and lowering the ... Jenkins writes to President-elect Trump that "Our nearly 38 ... on you to protect their Medicare and Social Security ...
Breaking Medicine Technology: